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OBJECTIVE. To report a large outbreak of Clostridium difficile infection (CDI; ribotype 027) between June 2007 and August 2008, describe 
infection control measures, and evaluate the impact of restricting the use of fluoroquinolones in controlling the outbreak. 
DESIGN. Outbreak investigation in 3 acute care hospitals of the Northern Health and Social Care Trust in Northern Ireland. 
INTERVENTIONS. Implementation of a series of CDI control measures that targeted high-risk antibiotic agents (ie, restriction of fluo-
roquinolones), infection control practices, and environmental hygiene. 
RESULTS. A total of 318 cases of CDI were identified during the outbreak, which was the result of the interaction between C. difficile 
ribotype 027 being introduced into the affected hospitals for the first time and other predisposing risk factors (ranging from host factors 
to suboptimal compliance with antibiotic guidelines and infection control policies). The 30-day all-cause mortality rate was 24.5%; however, 
CDI was the attributable cause of death for only 2.5% of the infected patients. Time series analysis showed that restricting the use of 
fluoroquinolones was associated with a significant reduction in the incidence of CDI (coefficient, —0.054; lag time, 4 months; P = .003). 
CONCLUSION. These findings provide additional evidence to support the value of antimicrobial stewardship as an essential element of 
multifaceted interventions to control CDI outbreaks. The present CDI outbreak was ended following the implementation of an action plan 
improving communication, antibiotic stewardship, infection control practices, environmental hygiene, and surveillance. 
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Clostridium difficile is the primary cause of nosocomial in- Ireland was reported in 2005 in a patient with diarrhea trans-
fectious diarrhea, causing significant morbidity and increas- ferred from a hospital in the United Kingdom (UK).8 In 
ing healthcare costs.1 In recent years, a change in virulence Northern Ireland, a survey of C. difficile ribotypes was un-
of prevalent C. difficile strains has been associated with the dertaken between September and December 2006; no cases 
occurrence of a number of outbreaks with increased severity of CDI ribotype 027 were identified.2 In June 2007, however, 
and significant mortality.2"6 This change involved the emer- the first case of infection due to this ribotype was reported 
gence of a new strain, referred to as PCR ribotype 027.2,3 The in the Antrim Area Hospital. The index patient was of ad-
increased virulence of C. difficile ribotype 027 is associated vanced age and had multiple comorbidities. Ribotyping was 
with mutations to the tcdC gene, which interferes with the requested because of the severity of the patient's illness. Sub-
downregulation of toxins A and B (the main C. difficile vir- sequently, a rise in the incidence of CDI was noted in 3 acute 
ulence factors), leading to the production of high levels of care hospitals within the Northern Health and Social Care 
these toxins.3,5'7 The first case of C. difficile infection (CDI) Trust (hereafter, "the Trust"), with an accompanying increase 
due to ribotype 027 that was recognized in the Republic of in the reported number of cases of C. difficile ribotype 027 
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infection. In recognition of higher than expected numbers of 
cases of CDI, the Trust declared an outbreak in January 2008. 
The objectives of this article are to report the occurrence of 
a large multihospital outbreak of CDI due to ribotype 027 
in Northern Ireland, to describe infection control practices, 
and to evaluate the impact of restricting the use of fluoro-
quinolones by utilizing time series analysis.9"11 
METHODS 
As this work was considered a case review and outbreak in-
vestigation, ethical approval and the approval of the Trust's 
research and development department were not required; the 
study has been registered with the research and development 
department. 
Setting and Study Period 
The Trust consists of 4 acute care hospitals (907 beds) and 4 
rehabilitation/palliative care hospitals (141 beds). The inves-
tigation consisted of 2 components: (1) a description of the 
CDI outbreak and the infection control measures applied dur-
ing the outbreak (June 16, 2007 through August 31, 2008) and 
(2) a retrospective ecological analysis that involved collecting 
monthly data on the usage of antibiotics and the incidence of 
CDI over a 5.5-year study period (January 2004 through June 
2009). The former component included only 3 affected acute 
care hospitals (Antrim Area Hospital [411 beds], Mid-Ulster 
Hospital [124 beds], and Whiteabbey Hospital [130 beds]) and 
2 rehabilitation/palliative care facilities (Braid Valley Hospital 
[36 beds] and Moyle Hospital [45 beds]). The latter component 
included only the affected acute care hospitals. 
Microbiology and Pharmacy Data 
The monthly incidence of CDI was obtained from the clinical 
microbiology information system over the study period. Data 
duplication was eliminated by using data for only the first 
test result positive for C. difficile if there was more than 1 
positive test result within 28 days, as this was considered a 
single episode. Within the hospital laboratory, clinical samples 
were processed according to routine microbiologic proce-
dures. All assays for C. difficile toxins A and B in feces from 
patients with colitis-like symptoms were performed in the 
microbiology laboratory at Antrim Area Hospital using an 
enzyme-linked immunoabsorbant assay (Premier). Isolates of 
putative C. difficile were referred to the Anaerobe Reference 
Laboratory at the University Hospital of Wales, Cardiff, for 
confirmation and typing. 
Prior to December 2007, ribotyping was requested on the 
basis of medical assessment of clinical severity. From the be-
ginning of December 2007, all C. difficile toxin-positive sam-
ples were cultured anaerobically, and those yielding growth 
of putative C. difficile were sent for ribotyping. PCR ribo-
typing was performed according to the method described by 
others,12 and the banding patterns produced were assigned 
to the PCR ribotyping library.13 
Prior to January 2008, in accordance with government 
guidelines, the testing of feces from all patients 65 years of 
age and older with diarrhea was the routine practice. The 
testing of feces for patients at least 2 years of age and younger 
than 65 years of age was done at physician request; toxin 
assays were done twice per day. Following the declaration of 
the outbreak in January 2008, diarrheal stool from all patients 
12 years of age and older was tested; toxin assays were done 
twice per day and when requested by the physician. 
For the purpose of this investigation, CDI was defined as 
being present if a patient had a toxin-positive test plus di-
arrhea (defined as an increased number [2 or more] of watery 
or liquid stools [ie, type 6 or 7, according to the Bristol Stool 
Scale]14 that is greater than normal for the patient, over a 
period of 24 hours). CDI was classified as severe if any of 
the following criteria were present: white blood cell count 
greater than 1,500 cells/mm3, temperature higher than 38.5°C, 
acutely rising blood creatinine (eg, an increase of more than 
50% above baseline), and evidence of severe colitis (abdom-
inal signs and radiologic findings). Clinical signs were ob-
tained by retrospective chart review using a standardized 
form. Cases of CDI were classified as follows:15 (1) hospital-
associated C. difficile disease was considered present in any 
patient with CDI symptom onset more than 48 hours after 
admission to the hospital or any patient with CDI symptom 
onset up to 48 hours after admission to a hospital, provided 
that symptom onset was less than 4 weeks after the last dis-
charge from a hospital; (2) community-associated C. difficile 
disease was considered present in any patient with CDI symp-
tom onset up to 48 hours after admission to a hospital, pro-
vided that symptom onset occurred more than 12 weeks after 
the previous discharge from a hospital; (3) indeterminate C. 
difficile disease was considered present in any case patient 
that did not fit any of the above criteria. 
The following epidemiological case definition was used for 
the outbreak: patients with a positive C. difficile toxin test 
result from June 16, 2007 and compatible symptoms who 
were inpatients in the affected hospitals when the sample was 
obtained. The case definition includes case patients up to 
August 31, 2008. This case definition was chosen to include 
the first confirmed case of infection with C. difficile ribotype 
027, which occurred on June 16, 2007; the outbreak was 
declared over in August 2008. The criteria for declaring the 
end of the outbreak were (1) a sustained reduction in the 
number of new cases of CDI each month to the level that 
could have been regarded as the Trust's baseline before the 
outbreak commenced, (2) a reduction in the number of case 
patients with ribotype 027 newly acquired in the hospital 
environment, (3) no evidence of patient-to-patient trans-
mission, and (4) evidence of successful implementation of 
the agreed control measures. 
To assess relationships existing between antibiotic use and 
the incidence of CDI, the monthly quantities of each anti-
biotic delivered for patient care to each ward of the affected 
acute care hospitals were obtained from the hospital phar-
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macy information system. These quantities were converted 
into defined daily doses (DDDs) following the recommen-
dations of the World Health Organization.16 
Antibiotic Restriction Policy 
The Trust had guidelines for the empirical treatment of all 
major clinical infectious syndromes. In January 2008, the 
empirical use of fluoroquinolones was restricted, with the 
exceptions of treatment for epididymo-orchitis, prostatitis, 
pelvic inflammatory disease, orbital cellulitis, and cellulitis in 
patients with penicillin allergy. Otherwise, use of a restricted 
antibiotic required exemption by a medical consultant, with 
monitoring by the hospital pharmacy in consultation with 
the Consultant Medical Microbiologist. 
Routine Infection Control Practices 
The Trust's infection control policies were consistent with 
national and international guidelines, which included regular 
hand hygiene between every patient contact. All patients with 
a diagnosis of CDI were placed in single room or cohort 
contact isolation. Detergent and water were used for general 
ward cleaning, while detergent followed by 1,000-ppm hy-
pochlorite solution was used for cleaning the isolation rooms 
on a daily basis and on discharge or transfer of the patient. 
Infection Control Practices during the Outbreak 
An action plan addressing communication, infection control 
practices, clinical management, environmental hygiene, and 
surveillance was agreed to by the Outbreak Control Team 
(OCT). Information leaflets on the nature of CDI and the 
measures to control it were issued to staff, patients, and visitors. 
Patient care equipment and environmental cleaning in all pa-
tient care areas, which included general wards and isolation 
rooms, was enhanced by the introduction of an intensive clean-
ing including the use of vaporized hydrogen peroxide and 
chemical disinfection with a chlorine-releasing agent. In general 
wards, patient care equipment and the environment were 
cleaned daily and on patient discharge or transfer using a chlo-
rine dioxide product in a one-step process; in isolation areas 
cleaning took place twice daily and on discharge or transfer 
using a two-step process: detergent followed by 1,000-ppm 
hypochlorite solution. An isolation ward with 8 single rooms 
and 4 bays, each containing 4 beds, was designated for CDI 
patients. All patients with laboratory-confirmed cases of CDI 
and patients with presumptive CDI who were unable to main-
tain personal hygiene were isolated; other patients with pre-
sumptive CDI were placed in open wards, with contact pre-
cautions being applied, until laboratory confirmation was 
received. A care bundle, the Saving Lives High Impact Inter-
vention number 7, was reinforced Trust-wide to control the 
spread of CDI.17 The latter identified 5 main key elements as 
being necessary to reduce the incidence of CDI: prudent an-
tibiotic use, correct hand hygiene, environmental decontami-
nation, personal protective equipment, and isolation and co-
hort nursing.17 The Infection Control Team (ICT) monitored 
use of the care bundle with support from 3 senior nurses 
seconded from their normal duties. Hospital Site Implemen-
tation Teams (HSITs), comprising a senior manager, ward nurs-
ing and medical staff, and Hotel Services staff, were formed 
to ensure that the OCT action plan was implemented. The 
Trust infection control policies were implemented in all clinical 
areas, and there was an ongoing program of audit of hand 
hygiene practices and environmental cleanliness. 
Mortality Determination 
Mortality was determined on the basis of the information 
provided by Northern Ireland Statistics and Research Agency 
from the General Register Office for registered deaths during 
the outbreak period. This information is based on the Medical 
Certificate of Cause of Death (MCCD), which is completed 
by a Registered Medical Practitioner who has treated the de-
ceased in the 28 days prior to death.18 On the MCCD, the 
cause of death can be included in part I (indicating that C. 
difficile infection was the disease or condition directly leading 
to death) or part II of the certificate (indicating that C. difficile 
was significant condition contributing to death but not related 
to the disease or condition causing it). 
Statistical Analysis 
The x2 test was used to determine whether there were signif-
icant differences in clinical severity and 30-day mortality be-
tween patients infected with ribotype 027 and others infected 
with non-027 ribotypes. This was performed using SPSS for 
Windows, version 17 (SPSS Institute). Autoregressive inte-
grated moving average (ARIMA) models, using the Box-
Jenkins method for analysis,19 were used to evaluate whether 
relationships existed between antibiotic use and the incidence 
of CDI, as described elsewhere.11 To evaluate the effect of the 
antibiotic restriction policy, dummy variables were created, 
whereby 0 and 1 represent the pre- and postintervention pe-
riods, respectively. A transfer function model that models a 
time series as a function of its past values and random errors 
was built. For each individual series, an ARIMA model was 
identified and fitted according to the Box and Jenkins meth-
odology.19 The model was identified by determining the 
ARIMA model orders (p, d, and q) using autocorrelation and 
partial autocorrelation. The model parameters were then es-
timated by the unconditional least squares method. Finally, the 
adequacy of the model was checked,11 and the statistical sig-
nificance of the parameters was determined. After identification 
of the multivariate transfer function models, the cross-corre-
lation function was determined by estimating the correlations 
between the series describing antibiotic use at different time 
lags and the CDI series. Significance tests for parameter esti-
mates were used to eliminate the unnecessary terms in the 
model. A P value of .05 was considered to be statistically sig-
nificant. The final model was derived by the econometric "gen-
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eral-to-specific" approach. All time series analyses were per-
formed using EViews 6 software (QMS). 
RESULTS 
In the affected hospitals, a marked increase in CDI incidence 
rates was observed in late 2007 and early 2008 (Figure 1); 
the mean annual CDI incidence rates, for the affected acute 
care hospitals for the 5 years from January 2004 to December 
2008 were 0.05, 0.07, 0.08, 0.12, and 0.11 cases per 100 bed-
days. The mean annual CDI incidence rates for each affected 
acute care hospital for these years were 0.05, 0.06, 0.09, 0.13, 
and 0.10 cases per 100 bed-days for Antrim Area Hospital; 
0.05, 0.06, 0.07, 0.09, and 0.13 cases per 100 bed-days for 
Whiteabbey Hospital; and 0.06,0.10,0.06,0.10, and 0.11 cases 
per 100 bed-days for Mid-Ulster Hospital. In 2007, the mean 
fluoroquinolone usage rates for Antrim Area Hospital, White-
abbey Hospital, and Mid-Ulster Hospital were 12, 13, and 9 
DDDs per 100 bed-days, respectively. In 2008 (following re-
strictions on the use of fluoroquinolone), the mean fluoro-
quinolone usage rates for these 3 hospitals was 2, 3, and 1 
DDDs per 100 bed-days, respectively. 
The median age of patients was 81 years, with 84% of the 
affected patients aged over 65 years. Of the 318 affected pa-
tients, the onset of illness occurred within 2 days after ad-
mission for 57 patients (18%). Of these 57 patients, 26 (8%) 
had been discharged from a Trust hospital within the 4 weeks 
prior to onset of CDI. A further 8 (3%) patients had been 
discharged from a Trust hospital between 4 and 12 weeks 
prior to onset of CDI. Twenty-three of the patients (7%) 
whose onset of symptoms occurred within 48 hours after 
admission had not been hospitalized in a Trust hospital in 
the 12 weeks before the onset of CDI. General characteristics 
of the affected patients (n = 318) during the outbreak period 
and a comparison of characteristics of C. difficile ribotype 
027-infected patients and those of non-027 C. difficile 
ribotype-infected patients are shown in Tables 1 and 2, 
respectively. 
A total of 154 of the 318 patients with CDI were identified 
as deceased from all causes up to October 21, 2008. One of 
those patients who died within 30 days was not identified by 
MCCD, giving a total of 155 deaths (48.7% of patients). 
Details of mortality rates in relation to overall mortality, mor-
tality within 30 days, and mortality after admission are shown 
in Table 3. Clinical outcomes (ie, nonsevere or severe) and 
30-day mortality for patients infected with ribotype 027 and 
for those infected with other identified ribotypes are shown 
in Table 4. No statistically significant differences were ob-
served. Of the 15 patients infected with ribotype 027 identified 
as deceased within 30 days (Table 4), 3 had C. difficile men-
tioned on part I of the MCCD and 8 had C. difficile mentioned 
on part II; 4 had no mention of C. difficile on the death 
certificate. Of the 19 patients infected with non-027 ribotypes 
identified as deceased within 30 days (Table 4), 2 had C. 
difficile mentioned on part I of the MCCD, 7 had C. difficile 
mentioned on part II, and 10 had no mention of C. difficile 
on the death certificate. 
The time series analysis model showed that restricting the 
use of fluoroquinolones by 1 DDD per 100 bed-days resulted 
4 months later in a significant reduction in the incidence of 
CDI, by 0.054 cases per 100 bed-days (Table 5). The deter-
mination coefficient {R2) of the final model was 0.66; that is, 
66% of the variation in the monthly incidence of CDI over 
the study period was explained by the factors included in the 
model. A graphical representation of the relationship between 
the monthly use of fluoroquinolones and the monthly inci-
dence of CDI is presented in Figure 1. 
D I S C U S S I O N 
Recent reports of CDI outbreaks of greater severity and sig-
nificant mortality associated with C. difficile ribotype 027 have 
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FIGURE i. Comparison of the monthly incidence of Clostridium difficile infection (CDI; thick line) and fluoroquinolone usage rate {thin 
line) at Antrim Area Hospital, Mid-Ulster Hospital, and Whiteabbey Hospital, January 2004 through June 2009. A, Admission of a patient 
with CDI ribotype 027 in June 2007. B, Laboratory results for this patient reported to the Northern Health and Social Care Trust. C, CDI 
outbreak declared; infection control measures and a fluoroquinolones restriction policy introduced. D, Outbreak declared over. 
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TABLE i. General Demographic and Clinical Characteristics of Patients with Clostridium difficile Infection (CDI) 
during the Outbreak Period (June 16, 2007, through August 31, 2008) 
Characteristic Value 
Median age (IQR), years" 
>65 years old 
Male sex 
Female-to-male ratio 
LOS, median (IQR), days 
In hospital 
In hospital prior to first positive CDI toxin test 
In hospital from first positive CDI toxin test to discharge 
Onset of illness within 2 days after admission 
Any status 
Discharged from a Trust hospital within 4 weeks prior to onset of CDI 
Discharged from a Trust hospital 4—12 weeks prior to onset of CDI 
Not hospitalized in a Trust hospital in the 12 weeks prior to onset of CDIb 
Comorbidity score' at admission, median (IQR) (n = 263) 
Type of ward admission 
Medical 
Surgical 
ICU 
Normal residence 
Nursing or residential home 
Long-stay hospital facility 
Own home 
Ribotyping results 
Samples sent for ribotypingd 
Samples failed to grow or were not able to be ribotyped 
Samples ribotyped 
Ribotype identified 
Ribotype 027 
Non-027 ribotype 
Ribotype 001 
Ribotype 078 
Others 
Clinical events in the 12 weeks prior to diagnosis 
Receipt of antibiotics6 
Receipt of proton pump inhibitors 
Gastrointestinal surgery 
Receipt of immunosuppressive therapy 
Receipt of prolonged laxative therapy 
Admission to hospital 
NOTE. Data are proportion (%) of patients, unless otherwise indicated. ICU, intensive care unit; IQR, interquartile 
range; LOS, length of stay; Trust, Northern Health and Social Care Trust. 
* Only completed and available records were included for each variable. 
b
 It was not possible to establish whether any of these patients had been in a hospital of another trust in the 28 
days before onset of CDI. 
c
 Comorbidity was scored using the Charlson Index as described by others.20 
d
 The ribotyping of all C. difficile isolates started only in late 2007 and early 2008. 
' Mostly amoxicillin-clavulanic acid (145/261 patients; 56%), piperacillin-tazobactam (81/261 patients; 31%), mac-
rolides (69/261 patients; 26%), and fluoroquinolones (46/261 patients; 18%). 
81 
266/318 
120/318 
1.7 
36 
11 
19 
57/318 
26/318 
8/318 
23/318 
1 
216/258 
37/258 
5/258 
63/258 
5/258 
190/258 
213/318 
39/213 
174/213 
71/174 
103/174 
24/174 
20/174 
59/174 
238/261 
160/268 
14/269 
23/263 
78/259 
132/256 
(71-87) 
(84) 
(38) 
: 1 
(16-72) 
(2-32) 
(8-36) 
(18) 
(8) 
(3) 
(7) 
(0-2) 
(84) 
(14) 
(2) 
(24) 
(2) 
(74) 
(67) 
(18) 
(82) 
(41) 
(59) 
(14) 
(12) 
(34) 
(91) 
(60) 
(5) 
(9) 
(30) 
(52) 
focused attention on the changing epidemiology of this path-
ogen. The objectives of this research were to report (in line 
with recent recommendation on outbreak investigations)21 a 
large multihospital outbreak of infection due to C. difficile 
ribotype 027 in Northern Ireland, to describe infection con-
trol practices, and to evaluate the impact of restricting the 
use of fluoroquinolones to control the outbreak. The majority 
of patients affected during the outbreak were exposed to 1 or 
more risk factors, such as host factors (eg, advanced age and 
comorbidities),3'22 exposure to factors that disrupt the normal 
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TABLE 2. Characteristics of Patients with Clostridium difficile Ribotype 027 Infection and Patients with Non-027 Ribotype Infection during 
the Outbreak Period (June 16, 2007, through August 31, 2008) 
Characteristic 
Median age (IQR), years 
Male sex 
LOS, median (IQR), days 
In hospital 
In hospital prior to onset of CDI 
In hospital following first onset of CDI to discharge 
Comorbidity score at admission, median (IQR) (ribotype 027, n = 54; other ribotypes, n = 74) 
Normal residence 
Nursing or residential home 
Long-stay hospital facility 
Own home 
Clinical events in the 12 weeks prior to diagnosis 
Receipt of antibiotics 
Receipt of proton pump inhibitors 
Gastrointestinal surgery 
Receipt of immunosuppressive therapy 
Receipt of prolonged laxative therapy 
Admission to hospital 
NOTE. Data are proportion (%) of patients, unless otherwise indicated. Only completed and available records were included for each 
variable. CDI, C. difficile infection; IQR, interquartile range; LOS, length of stay. 
Ribotype 027 
infection 
82 (75-87) 
23/67 (34) 
37 (17-76) 
10 (3-25) 
24 (9-55) 
1 (0-2) 
10/40 (25) 
1/40 (3) 
29/40 (73) 
45/45 (100) 
22/44 (50) 
3/45 (7) 
4/41 (10) 
15/39 (38) 
19/35 (54) 
Non-027 ribotype 
infection 
82 (72-88) 
35/95 (37) 
37 (25-81) 
12 (3-31) 
22 (10-42) 
1 (1-3) 
22/73 (30) 
1/73 (1) 
50/73 (69) 
71/76 (93) 
41/78 (53) 
5/78 (6) 
6/77 (8) 
20/75 (27) 
38/70 (54) 
protective intestinal microflora (ie, broad-spectrum antibiot-
ics),23"25 the use of gastric acid-suppressive agents,26"28 and poor 
infection control practices (eg, relating to the healthcare en-
vironment, and healthcare workers' compliance with hand 
hygiene).3,29 Auditing of compliance for adequate environ-
mental cleanliness and antibiotic stewardship before the out-
break occurred showed that these practices were sub-
optimal.30'31 
The analysis of the ribotyped C. difficile isolates (during 
the outbreak period) showed that ribotype 027 was the most 
frequendy identified strain (41% of isolates), highlighting the 
predominance of this ribotype in the outbreak. The 30-day 
all-cause mortality rate observed in this outbreak (24.5%) 
was similar to that in other outbreaks.32"34 However, CDI was 
the attributable cause of death for 2.5% of the C. difficile-
infected patients who died within 30 days. Although a number 
of studies have reported on the contribution of ribotype 027 
to greater disease severity and mortality,35"38 our analysis 
showed no statistically significant difference in the 30-day 
mortality and clinical severity between patients infected with 
ribotype 027 and patients infected with non-027 ribotypes. 
This finding could be related to the patients' different sus-
ceptibility profiles—which patients were affected by exposure 
to one or more of the previously mentioned risk factors— 
and the impact of the isolation ward in maximizing clinical 
management skill and experience. A single group of clinicians 
and nurses were looking after CDI patients in the designated 
isolation ward. This may have led to the development of high 
levels of skill in the clinical assessment and management of 
people with CDI and the ability to react more quickly to the 
clinical impact of CDI ribotype 027 to mitigate its effect. Of 
note is that 12% of the non-027 ribotype isolates were C. 
difficile ribotype 078, an emerging strain that was reported 
as having mechanisms for toxin hyperproduction similar to 
those of ribotype 027.2 The assessment of comparative clinical 
severity between patients infected with C. difficile ribotype 
027 and those infected with other ribotypes requires further 
investigation with a larger sample size to allow the construc-
tion of multivariate models, which should include other fac-
tors that may have influenced our findings, for example, age, 
morbidity on admission, and effects of ribotype 078 infection. 
Thus, a definitive conclusion in relation to this assessment 
was not possible, and these findings must therefore be in-
terpreted with caution. 
The investigation showed temporal relationships between 
the use of certain antibiotic classes and the incidence of CDI. 
Restricting the use of fluoroquinolones was associated with 
a significant reduction in the incidence of CDI, confirming 
fluoroquinolones as high-risk agents.25,39 In addition, the anal-
ysis showed that the use of amoxicillin-clavulanic acid and 
macrolides was also positively correlated with the incidence 
of CDI. However, second- and third-generation cephalospo-
rins did not appear as significant variables in the model, since 
their usage rate was already very low within the Trust. The 
control of antibiotics within the Trust has been scrutinized 
over a long period of time.40 This analysis led to more robust 
guidance on the use of antibiotics to be developed and in-
troduced in the study site hospitals in 1995, with a significant 
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TABLE 3. Mortality Rates of the Affected Patients during the Clostridium difficile Infection (CDI) Outbreak (June 16, 
2007, through August 31, 2008) 
No. (%) of patients (n = 318) 
Variable Mortality within 30 days Mortality after 30 days Overall mortality' 
C. difficile mentioned on MCCD 38 (11.9) 
C. difficile recorded in part I of the MCCD 8 (2.5) 
C. difficile recorded in part II of the MCCD 30 (9.4) 
Total, all causes 78 (24.5) 
13 (4.0) 
5 (1.5) 
8 (2.5) 
77 (24.2) 
51 (16.0) 
13 (4.1) 
38 (11.9) 
155 (48.7) 
NOTE. MCCD, Medical Certificate of Cause of Death. 
" The 30-day and the after-30-day mortality rates grouped together. 
revision in 1999 specifically to restrict the use of broad-spec-
trum cephalosporins in response to an outbreak of CDI, as 
there was strong association with the use of these agents.41 
All antibiotic usage policies were regularly reviewed and up-
dated. 
Importantly, it has been emphasized that an approach com-
bining optimal infection control practices with antimicrobial 
stewardship is required in order to interrupt transmission 
and successfully control CDI outbreaks.25,42'43 The current CDI 
outbreak ended after the implementation of a series of con-
trolling measures that targeted high-risk antibiotic agents (ie, 
restricting the use of fluoroquinolones), infection control 
practices, and environmental hygiene; this was achieved 
through the extended ICT and HSIT ensuring that ward staff 
understood their role in controlling the outbreak. The im-
plementation of the infection control and environmental hy-
giene measures was uniform among the affected hospitals, 
with the exception of the isolation ward, which was estab-
lished only in Antrim Area Hospital. This isolation ward re-
ceived patients from all hospitals within the Trust when they 
were fit to be transferred; patients unfit for transfer were 
isolated in single rooms in their admitting hospitals. Auditing 
of the compliance for adequate environmental cleanliness30 
and antibiotic stewardship (data provided by the European 
Surveillance of Antimicrobial Consumption network [ESAC] 
May 2009 survey) following the declaration of the outbreak 
showed a remarkable improvement in these practices. The 
ESAC 2009 survey results showed that compliance with the 
Antrim Area Hospital antibiotic guidelines was 70%, while a 
previous audit for compliance with the hospital guidelines in 
surgical wards (in 2006) showed a lower compliance rate 
(31%).31 Similarly, external audits of environmental cleanli-
ness (January 2008) showed that all hospitals within the Trust 
improved their compliance scores for adequate environmen-
tal cleanliness. Antrim Area Hospital scored 89% in a January 
2008 audit, while in a previous audit (January 2007), the 
hospital score was 77%.30 These results may provide an in-
dication that the implementation of the outbreak-controlling 
measures was successful. Nevertheless, as the emergence of 
CDI is multifactorial, it is difficult to determine the relative 
contributions made by infection control measures and an-
timicrobial stewardship. This remains an area that needs fur-
ther investigation. 
The study has some limitations. First, although analysis of 
data included both nosocomial cases of CDI in Trust hospitals 
and other CDI cases, the percentage of patients who had not 
been hospitalized in a Trust hospital in the 12 weeks prior 
to onset of CDI was only 7% (Table 1), These patients were 
TABLE 4. Clinical Outcome and 30-Day Mortality for Patients Identified with Clostridium difficile 
Ribotype 027 Infection and Patients with Non-027 Ribotype Infection during the Outbreak Period 
(June 16, 2007, through August 31, 2008) 
Proportion (%) of patients 
Variable 
Ribotype 027 
infection 
Non-027 ribotype 
infection 
Clinical severity at date of first CDI-positive sample .836 
Nonsevere 34/46 (74) 74/98 (76) 
Severe 12/46 (26) 24/98 (24) 
Clinical severity at worst point during this episode .297 
Nonsevere 26/39 (67) 68/90 (76) 
Severe 13/39 (33) 22/90 (24) 
30-day mortality .713 
Alive 52/67 (78) 76/95 (80) 
Dead 15/67 (22) 19/95 (20) 
NOTE. Only completed and available records were included for each variable. CDI, C. difficile 
infection. 
a
 Statistically significant at P< .05. 
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TABLE 5. Estimated Multivariate Time Series Analysis Model for the Impact of Restricting 
the Use of Fluoroquinolones on the Monthly Incidence of Clostridium difficile Infection (CDI) 
(R2 = 0.66) 
Term 
Lag time, 
months' Coefficient ± SEb T ratio 
Fluoroquinolone use restriction 
Macrolide use 
Amoxicillin-clavulanic acid 
AR 
MA 
4 
4 
2 
1 
3 
-0.054044 ± 0.017585 
0.002935 ± 0.000848 
0.001797 ± 0.000528 
0.495220 ± 0.118818 
0.515774 ± 0.116495 
-3.073 
3.460 
3.401 
4.167 
4.427 
.0033 
.0010 
.0012 
.0001 
<.0001 
NOTE. AR, autoregressive term representing past incidence density of CDI; MA, moving 
average term representing past disturbances in the incidence density of CDI. 
* Delay necessary to observe the effect. 
b
 Size and the direction of the effect. 
included in the study, as it was not possible to establish 
whether any of these patients had been in a hospital of an-
other trust in the 28 days before onset of CDI. However, it 
is unlikely that such a low percentage (7%) can influence the 
findings. Second, it was not possible to rule out the possibility 
that there had been unrecognized cases of CDI due to ribotype 
027 before June 2007. Third, the CDI mortality was deter-
mined on the basis of MCCDs, which may lack accuracy and 
data completeness. The Trust addressed this issue from early 
in the outbreak by having an independent review of case notes 
of toxin-positive patients who were known to have died in 
2007 in the Trust (of all causes) by 2 senior clinicians, one 
of whom was an external gastroenterologist. C. difficile was 
reported as significant condition contributing to death more 
frequently in the MCCD than in the reviewed case notes. The 
observed differences may have influenced the findings; how-
ever, such an error in completion of the MCCD is more likely 
to affect infections due to all C. difficile ribotypes rather than 
being selective for a specific ribotype. Following the decla-
ration of the outbreak in 2008, the Trust reinforced guidance 
on completion of MCCD and established more robust mea-
sures to monitor deaths associated with CDI using direct 
reporting to a senior clinician and the reviewing Infection 
Control Prevention team data. The Trust would note that all 
reported figures are provisional, pending the completion of 
the "Public Inquiry into the Outbreak of C. difficile in 
Northern Trust Hospitals." Finally, the assessment of the im-
pact of restricting fluoroquinolones did not take into account 
the changes in infection control practices that took place as 
a result of the CDI outbreak. However, such parameters may 
contribute to the 34% of the variance in CDI rates that was 
not explained by the final model. 
In conclusion, the occurrence of this multihospital CDI 
outbreak was the result of the interaction between C. difficile 
ribotype 027 being introduced into the affected hospitals for 
the first time and other predisposing risk factors (ranging 
from host factors to less than optimal compliance with hos-
pital infection control and environmental hygiene policies) 
that facilitated its spread. These findings provide additional 
evidence to support the value of antimicrobial stewardship 
as an essential element of multifaceted interventions to con-
trol CDI outbreaks. The CDI outbreak was controlled by the 
implementation of an action plan improving communication, 
antibiotic stewardship, infection control practices, environ-
mental hygiene, and surveillance. 
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